Search Results
Nov 04, 2025, 09:00 ET Holiday Stress Driving Americans to Spend More, Increase Borrowing, and Pick Up Extra Jobs, New MoneyLion Survey Finds
their bank statements after the holidays, with anxiety emerging as the most common feeling (36%) after their review — impacting women more than men (42% vs 30%). More Shoppers are Turning to Credit, But Aren't Aware of the Risks: 84% of Americans plan
More news about: Gen Digital Inc.
Nov 04, 2025, 09:00 ET Only half of American millionaires plan to leave an inheritance - and just one-third consider themselves "wealthy," according to Northwestern Mutual Planning & Progress Study
I have good clarity on exactly how much I can spend now vs. save for later
More news about: Northwestern Mutual
Nov 04, 2025, 08:30 ET HiBob Launches Bob Finance, Uniting HR, Payroll, and Finance in One Platform
decisions. Cross-Functional Collaboration: Align Finance, HR, and budget owners with live plan-vs-actual views. AI-Driven Insights: Bob AI spots trends, explains variances, and
More news about: HiBob
Nov 04, 2025, 08:04 ET Tarps Plus Unveils "Billy Mac: The Apocalypse-Proof Tarp" -- The Most Outrageous Tarp Commercial Ever Made
Product ProofThe "Apocalypse-Proof Tarp" commercial marks the latest evolution of the Billy Mac series, following viral hits like "Billy Mac vs. the Texas Windstorm" and "The Backyard BBQ Disaster." Each video combines slapstick humor with genuine product performance — showing that Tarps Plus
More news about: TarpsPlus
Nov 04, 2025, 08:00 ET Holiday Gut Punch: Survey Shows Women More Likely to Serve as 'Holiday CEO' and Their Digestive Health Suffers
The survey reveals that those who "do it all" by shouldering many of the cooking, shopping, and hosting responsibilities are most commonly women (20%, vs. 8% of men). Overwhelmingly, 76% of all respondents reported experiencing gastrointestinal stress and discomfort during the holiday
More news about: Oshi Health
Nov 04, 2025, 08:00 ET Oasis Security and Sequoia Launch the First Practitioner-Built Governance Framework for Agentic AI Access
Cyberhaven 2025). Organizations without a formal AI strategy have only a 37% success rate in adoption vs. 80% for those with clear governance (
More news about: Oasis Security
Nov 04, 2025, 08:00 ET Calliditas Therapeutics to Present at the American Society of Nephrology Kidney Week
Abstract No. FR-PO0804 Title: "Absolute Proteinuria over Time with Nefecon vs. Placebo in Patients with IgAN: Results from the Phase 3 NefIgArd Trial"Date and time: November 7, 10 am to 12 pm CTPresenter:
More news about: Asahi Kasei Corporation
Nov 04, 2025, 07:30 ET Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications
Prostate Cancer Data Highlights Superior efficacy and durability vs 177Lu-PSMA-617 (active agent in Pluvicto®), 225Ac-PSMA-617, and ARPI enzalutamide (active agent in Xtandi®), with durable tumor
More news about: Actinium Pharmaceuticals, Inc.
Nov 04, 2025, 07:30 ET Wingstop Inc. Reports Fiscal Third Quarter Financial Results
Skipworth, President & Chief Executive Officer. "We opened 114 net new restaurants in the quarter, which translated to more than 19% unit growth vs prior year. Our sustained development momentum in 2025, coupled with strong margin performance, reinforces our confidence in our long-term vision to
More news about: Wingstop Restaurants Inc.
Nov 04, 2025, 07:00 ET Marriott International Reports Third Quarter 2025 Results
vs. Fourth Quarter 2024
More news about: Marriott International, Inc.
Nov 04, 2025, 07:00 ET ANYWHERE REAL ESTATE INC. REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
2025 vs. 2024 KEY DRIVERS
More news about: Anywhere Real Estate Inc.
Nov 04, 2025, 06:20 ET Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by 2033, Driven by Accelerated Immunotherapy Approvals and Precision Medicine Advances - DataM Intelligence
expanded Carvykti's label to earlier-line MM patients following phase III CARTITUDE-4 success, improving progression-free survival by 74% vs standard care. Bristol Myers Squibb initiated phase II studies for Abecma in combination
More news about: DataM Intelligence 4 Market Research LLP
Nov 04, 2025, 06:00 ET Eve Holding, Inc. Reports Third Quarter 2025 Results
our suite of products and solutions for UAM, including the Master Service Agreement (MSA) with Embraer. R&D expenses were $44.9 million in 3Q25 vs. $32.4 million in 3Q24. R&D continues to demand increased engineering engagement with Embraer, as well as additional program development activities
More news about: Eve Holding, Inc.
Nov 04, 2025, 06:00 ET Ball Reports Third Quarter 2025 Results
Third quarter U.S. GAAP total diluted earnings per share of $1.18 vs. 65 cents in 2024 Third quarter comparable diluted earnings per share of $1.02 vs. 91 cents in 2024, an increase of 12.1% Global aluminum packaging shipments
More news about: Ball Corporation
Nov 04, 2025, 03:00 ET Elsevier's global survey of 3,000 researchers reveals less than half have time to do research but see AI as transformative if given right tools
time: 79% in China vs. 54% in the US, and 57% in the UK To improve quality of work: 60% in China vs. 22% in the US, and 17% in the UK To accelerate discovery: 49% in China vs. 30% in the US, and
More news about: Elsevier Limited
Nov 04, 2025, 01:00 ET StockGro Sparks Innovation Through UAE's Largest Student Hackathon at BITS Pilani Dubai
platform for designing trading strategies Liquidity Tracker – Dashboard tracking institutional vs. retail activity AI Stock Picks – Model predicting stocks via consumer–supplier trends
More news about: StockGro
Nov 04, 2025, 01:00 ET StockGro Sparks Innovation Through UAE's Largest Student Hackathon at BITS Pilani Dubai
platform for designing trading strategies Liquidity Tracker – Dashboard tracking institutional vs. retail activity AI Stock Picks – Model predicting stocks via consumer–supplier trends
More news about: StockGro
Nov 03, 2025, 22:23 ET 【2025 ASH】 亞盛醫藥Bcl-2抑制劑利沙托克拉兩項臨床研究入選，含1項口頭報告！
Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational
More news about: 亞盛醫藥
Nov 03, 2025, 20:22 ET 【2025 ASH】亞盛醫藥耐立克®多項研究入選，POLARIS-1研究數據首次發布
Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase
More news about: 亞盛醫藥
Nov 03, 2025, 16:50 ET Asetek - Q3 2025: Firming Up The Growth Outlook Amid Near-term Market Challenges
Q3 SimSports revenue at $1.3 million, stable vs. Q2 and in line with expectations as U.S. import tariffs continue to impact demand ($1.5 million in Q3 2024)
More news about: Asetek
Nov 03, 2025, 16:30 ET Centerspace Reports Third Quarter 2025 Financial & Operating Results and Updates 2025 Financial Outlook
Q3 2025 vs. Q3 2024
More news about: Centerspace
Nov 03, 2025, 16:15 ET CNO Financial Group Reports Third Quarter 2025 Results
FINANCIAL SUMMARY (continued) Management vs. GAAP Measures(Dollars in millions, except per share data)(Unaudited) Shareholders' equity, excluding accumulated
More news about: CNO Financial Group
Nov 03, 2025, 16:05 ET PRA Group Reports Third Quarter 2025 Results
Q3 2025 Highlights (vs. Q3 2024) Total cash collections of $542.2 million,
More news about: PRA Group, Inc.
Nov 03, 2025, 15:00 ET Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism
refined modified Miller score (42.1% vs. 15.6% relative reduction; P < 0.001) Early physiological recovery with significantly lower heart rate (80.0 bpm vs 86.4 bpm; P = 0.022) and less tachycardia (heart rate > 100, 2.2% vs 20%; P = 0.008), reduced supplemental
More news about: Penumbra, Inc.
Nov 03, 2025, 13:09 ET ESGFIRE Initiates Coverage on Charbone Corporation - A Rare Chance in the Fast-Growing Hydrogen Revolution
delivers projected EBITDA in the next 1–2 years, the stock is very cheap on an absolute basis (low single-digit EV/EBITDA). Moreover, relative valuation vs. peers and an independent appraisal both indicate a higher potential value. This suggests that the market is taking a "wait and see" approach – understandable
More news about: Charbone Hydrogen Corporation